Zealand Pharma A/S Stock Price Today (NSE: ZEAL)
Fundamental Score
Zealand Pharma A/S Share Price Live NSE/BSE & Institutional Fundamental Analysis
Zealand Pharma A/S share price today is ₹74.00, up +0.00% on NSE/BSE as of 8 February 2026. Zealand Pharma A/S (ZEAL) is a Small-cap company in the Logistics Solution Provider sector with a market capitalisation of ₹132.43 (Cr). The 52-week high for ZEAL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 13.23x, ZEAL is currently trading below its industry average P/E of 25.23x. The company has a Return on Equity (ROE) of 19.60% and a debt-to-equity ratio of 0.29.
Zealand Pharma A/S Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Zealand Pharma A/S Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Zealand Pharma A/S Share Price: A ROCE-Focused Analysis
The Logistics Solution Provider sector, often overlooked in favour of pure-play e-commerce, presents unique opportunities for investors. The efficiency of capital employed is paramount for companies facilitating the movement of goods. Our analysis focuses on Zealand Pharma A/S share price (₹74.0), examining its financial health through the lens of Return on Capital Employed (ROCE). With a Price-to-Earnings (PE) ratio of 13.23 and an impressive ROCE of 23.8%, Zealand Pharma A/S appears promising at first glance. This analysis forms part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra.
The standout figure is the ROCE. A 23.8% ROCE signifies that for every ₹100 of capital invested in the business, Zealand Pharma A/S generates ₹23.8 in earnings. This level of efficiency is critical for building a durable competitive advantage, or "moat." A high ROCE suggests effective management in deploying capital, strong pricing power, and/or well-managed operational costs. This contrasts with potentially lower ROCE scenarios where margins are thin and competition is fierce.
Comparing Zealand Pharma A/S to its peers is crucial. While a detailed comparison requires deeper analysis, consider how Zealand Pharma A/S differs from
RAPID FLEET MGT SERVICE L. The management quality at Rapid Fleet Mgt Service L, influencing factors like capital allocation and operational efficiency, could explain any disparities in financial performance with Zealand Pharma A/S. A high ROCE at Zealand Pharma A/S, when contrasted with peers, might suggest superior management capabilities in extracting value from its investments.The significance of a high ROCE extends beyond immediate profitability. It allows Zealand Pharma A/S to reinvest earnings at higher rates, potentially fueling further growth and strengthening its market position. This self-reinforcing cycle can lead to a widening of the economic moat over time. Further due diligence on debt levels, working capital management, and the sustainability of its ROCE over the long term are necessary to fully assess Zealand Pharma A/S's investment potential. Observational data suggests its financial performance warrants a deeper look.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zealand Pharma A/S Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZEAL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (19.60%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (23.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 13.23 vs Industry: 25.23)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (36.90% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (62.94% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.29)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (8.56x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.40%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Profit Decline Concern (-49.73%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-12.34% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-5.07 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.19%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Zealand Pharma A/S Financial Statements
Comprehensive financial data for Zealand Pharma A/S including income statement, balance sheet and cash flow
About ZEAL (Zealand Pharma A/S)
Zealand Pharma A/S (ZEAL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Logistics Solution Provider sector with a current market capitalisation of ₹132.43 (Cr). Zealand Pharma A/S has delivered a Return on Equity (ROE) of 19.60% and a ROCE of 23.80%. The debt-to-equity ratio stands at 0.29, reflecting the company's capital structure. Investors tracking ZEAL share price can monitor key metrics including P/E ratio, promoter holding of 73.40%, and quarterly earnings growth.
Company Details
ZEAL Share Price: Frequently Asked Questions
What is the current share price of Zealand Pharma A/S (ZEAL)?
As of 08 Feb 2026, 11:51 am IST, Zealand Pharma A/S share price is ₹74.00. The ZEAL stock has a market capitalisation of ₹132.43 (Cr) on NSE/BSE.
Is ZEAL share price Overvalued or Undervalued?
ZEAL share price is currently trading at a P/E ratio of 13.23x, compared to the industry average of 25.23x. Based on this relative valuation, the Zealand Pharma A/S stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ZEAL share price?
The 52-week high of ZEAL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Zealand Pharma A/S share price?
Key factors influencing ZEAL share price include quarterly earnings growth (Sales Growth: 0.56%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Zealand Pharma A/S a good stock for long-term investment?
Zealand Pharma A/S shows a 5-year Profit Growth of 62.94% and an ROE of 19.60%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.29 before investing in ZEAL shares.
How does Zealand Pharma A/S compare with its industry peers?
Zealand Pharma A/S competes with major peers in the Logistics Solution Provider. Investors should compare ZEAL share price P/E of 13.23x and ROE of 19.60% against the industry averages to determine competitive standing.
What is the P/E ratio of ZEAL and what does it mean?
ZEAL share price has a P/E ratio of 13.23x compared to the industry average of 25.23x. Investors pay ₹13 for every ₹1 of annual earnings.
How is ZEAL performing according to Bull Run's analysis?
ZEAL has a Bull Run fundamental score of 51.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ZEAL belong to?
ZEAL operates in the Logistics Solution Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Zealand Pharma A/S share price.
What is Return on Equity (ROE) and why is it important for ZEAL?
ZEAL has an ROE of 19.60%, which indicates excellent management efficiency. ROE measures how efficiently Zealand Pharma A/S generates profits from shareholders capital.
How is ZEAL debt-to-equity ratio and what does it indicate?
ZEAL has a debt-to-equity ratio of 0.29, which indicates conservative financing with low financial risk.
What is ZEAL dividend yield and is it a good dividend stock?
ZEAL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Zealand Pharma A/S shares.
How has ZEAL share price grown over the past 5 years?
ZEAL has achieved 5-year growth rates of: Sales Growth 36.90%, Profit Growth 62.94%, and EPS Growth -12.34%.
What is the promoter holding in ZEAL and why does it matter?
Promoters hold 73.40% of ZEAL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Zealand Pharma A/S.
What is ZEAL market capitalisation category?
ZEAL has a market capitalisation of ₹132 crores, placing it in the Small-cap category.
How volatile is ZEAL stock?
ZEAL has a beta of N/A. A beta > 1 suggests the Zealand Pharma A/S stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ZEAL operating profit margin trend?
ZEAL has a 5-year average Operating Profit Margin (OPM) of 7.56%, indicating the company's operational efficiency.
How is ZEAL quarterly performance?
Recent quarterly performance shows Zealand Pharma A/S YoY Sales Growth of 0.56% and YoY Profit Growth of -49.73%.
What is the institutional holding pattern in ZEAL?
ZEAL has FII holding of 0.00% and DII holding of 2.19%. Significant institutional holding often suggests professional confidence in the Zealand Pharma A/S stock.